Kavya Keerthana: A Potentially Important Advance in Polycythemia Vera
Kavya Keerthana, Hematologist at Prime Health, shared a post on LinkedIn:
“A potentially important advance in Polycythemia Vera (PV).
In PV, excess red blood cells increase the risk of blood clots, stroke and heart attack.
For years, regular phlebotomy has been a cornerstone of treatment—but repeated blood removal can also lead to iron deficiency.
The FDA has approved rusfertide, a hepcidin mimetic that offers a different approach by regulating iron availability and reducing excessive red blood cell production.
In the Phase 3 VERIFY trial, 76.9 percent of patients receiving rusfertide achieved clinical response, with fewer phlebotomies and improvements in symptoms such as fatigue.
A fascinating shift in how we think about managing PV.”
Find more posts featuring Kavya Keerthana on Hemostasis Today.
-
Sep 2, 2026, 09:26Mohammad Zuryan: Pre-Marital Genetic Screening for Thalassemia Prevention
-
Sep 2, 2026, 09:23Mohammed Salman: 9 Key Changes in the Fifth Universal Definition of Myocardial Infarction
-
Sep 2, 2026, 07:02Christoph B. Olivier: Rapid Platelet Inhibition in Acute Coronary Syndromes
-
Sep 2, 2026, 06:38Gene Therapy for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Sep 2, 2026, 06:32Sanjay Batra: Exploring What Lies Beyond Platelet Counts
-
Sep 2, 2026, 06:22Wolfgang Miesbach: A New Guideline for Critical Bleeding in ITP
-
Sep 2, 2026, 06:03Clémentine Sarkozy: A New Chapter for Hematology at Institut Curie
-
Sep 1, 2026, 18:13Ramsha Batool: Chemotherapy-Induced Anemia Impacts Quality of Life in Breast Cancer
-
Sep 1, 2026, 18:09Natalya Shynhera: Using Anemia to Teach Medical English in Real Clinical Practice